[1. DE BRAEKELEER E., DOUET-GUILBERT N., and DE BRAEKELEER M., RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol, 2014. 7(3): p. 347–357.10.1586/17474086.2014.903794]Search in Google Scholar
[2. GIRI S., PATHAK R., ARYAL M.R., KARMACHARYA P., and BHATT V.R., Second primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study. Future Oncol, 2017. 13(17): p. 1455–1457.10.2217/fon-2017-0077]Search in Google Scholar
[3. THULER L.C.S. and POMBO-DE-OLIVEIRA M.S., Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. Ann Hematol, 2017. 96(3): p. 355–362.10.1007/s00277-016-2846-0]Search in Google Scholar
[4. DINMOHAMED A.G. and VISSER O., Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. Stem Cell Investig, 2019. 6: p. 37–37.10.21037/sci.2019.10.03]Search in Google Scholar
[5. KANTARJIAN H.M., KEATING M.J., WALTERS R.S., ESTEY E.H., MCCREDIE K.B., SMITH T.L., et al., Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med, 1986. 80(5): p. 789–97.10.1016/0002-9343(86)90617-0]Search in Google Scholar
[6. TALLMAN M.S., ANDERSEN J.W., SCHIFFER C.A., APPELBAUM F.R., FEUSNER J.H., OGDEN A., et al., All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997. 337(15): p. 1021–8.10.1056/NEJM1997100933715019321529]Search in Google Scholar
[7. FENAUX P., CASTAIGNE S., DOMBRET H., ARCHIMBAUD E., DUARTE M., MOREL P., et al., All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood, 1992. 80(9): p. 2176–81.10.1182/blood.V80.9.2176.2176]Search in Google Scholar
[8. LO-COCO F., AVVISATI G., VIGNETTI M., THIEDE C., ORLANDO S.M., IACOBELLI S., et al., Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med, 2013. 369(2): p. 111–121.10.1056/NEJMoa130087423841729]Search in Google Scholar
[9. SANZ M.A., MONTESINOS P., RAYÓN C., HOLOWIECKA A., DE LA SERNA J., MILONE G., et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010. 115(25): p. 5137–5146.10.1182/blood-2010-01-26600720393132]Search in Google Scholar
[10. MICOL J.B., RAFFOUX E., BOISSEL N., LENGLINE E., CANET E., DANIEL M.T., et al., Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer, 2014. 50(6): p. 1159–68.10.1016/j.ejca.2013.11.02324440088]Search in Google Scholar
[11. LEHMANN S., RAVN A., CARLSSON L., ANTUNOVIC P., DENEBERG S., MÖLLGÅRD L., et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011. 25(7): p. 1128–1134.10.1038/leu.2011.7821502956]Search in Google Scholar
[12. PAGONI M., GAROFALAKI M., PANITSAS F., MANOLA K., PSARRA K., ECONOMOPOULOS P., et al., Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis, 2011. 3(1): p. e2011053–e2011053.10.4084/mjhid.2011.053]Search in Google Scholar
[13. KARIM F., SHAIKH U., ADIL S.N., and KHURSHID M., Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Med J, 2014. 55(8): p. 443–447.10.11622/smedj.2014105429409625189308]Search in Google Scholar
[14. SILVA W.F.D., JR., ROSA L.I.D., MARQUEZ G.L., BASSOLLI L., TUCUNDUVA L., SILVEIRA D.R.A., et al., Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil – Early Deaths Are Still a Problem. Clin Lymphoma Myeloma Leuk, 2019. 19(2): p. e116–e122.10.1016/j.clml.2018.11.00430509780]Search in Google Scholar
[15. PAULSON K., SEREBRIN A., LAMBERT P., BERGERON J., EVERETT J., KEW A., et al., Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol, 2014. 166(5): p. 660–666.10.1111/bjh.1293124780059]Search in Google Scholar
[16. PARK J.H., QIAO B., PANAGEAS K.S., SCHYMURA M.J., JURCIC J.G., ROSENBLAT T.L., et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011. 118(5): p. 1248–1254.10.1182/blood-2011-04-346437379094621653939]Search in Google Scholar
[17. MCCLELLAN J.S., KOHRT H.E., COUTRE S., GOTLIB J.R., MAJETI R., ALIZADEH A.A., et al., Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica, 2012. 97(1): p. 133.10.3324/haematol.2011.046490324894221993679]Search in Google Scholar
[18. LO-COCO F., AVVISATI G., VIGNETTI M., BRECCIA M., GALLO E., RAMBALDI A., et al., Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010. 116(17): p. 3171–9.10.1182/blood-2010-03-27619620644121]Search in Google Scholar
[19. SANZ M.A., LO COCO F., MARTÍN G., AVVISATI G., RAYÓN C., BARBUI T., et al., Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 2000. 96(4): p. 1247–1253.]Search in Google Scholar
[20. CHEN Y., KANTARJIAN H., WANG H., CORTES J., and RAVANDI F., Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer, 2012. 118(23): p. 5811–8.10.1002/cncr.27623418024622707337]Search in Google Scholar
[21. SANZ M.A., MONTESINOS P., VELLENGA E., RAYON C., DE LA SERNA J., PARODY R., et al., Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008. 112(8): p. 3130–4.10.1182/blood-2008-05-15963218664623]Search in Google Scholar
[22. ADES L., SANZ M.A., CHEVRET S., MONTESINOS P., CHEVALLIER P., RAFFOUX E., et al., Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008. 111(3): p. 1078–84.10.1182/blood-2007-07-099978]Search in Google Scholar
[23. KELAIDI C., CHEVRET S., DE BOTTON S., RAFFOUX E., GUERCI A., THOMAS X., et al., Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol, 2009. 27(16): p. 2668–76.10.1200/JCO.2008.18.4119]Search in Google Scholar
[24. SOBAS M., CZYŻ A., MONTESINOS P., ARMATYS A., HELBIG G., HOŁOWIECKA A., et al., Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. Clin Lymphoma Myeloma Leuk, 2019.10.1016/j.clml.2019.09.616]Search in Google Scholar
[25. JÁCOMO R.H., MELO R.A.M., SOUTO F.R., DE MATTOS É.R., DE OLIVEIRA C.T., FAGUNDES E.M., et al., Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica, 2007. 92(10): p. 1431.10.3324/haematol.10874]Search in Google Scholar
[26. SANZ M.A., MONTESINOS P., RAYON C., HOLOWIECKA A., DE LA SERNA J., MILONE G., et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010. 115(25): p. 5137–46.10.1182/blood-2010-01-266007]Search in Google Scholar
[27. DE LA SERNA J., MONTESINOS P., VELLENGA E., RAYON C., PARODY R., LEON A., et al., Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008. 111(7): p. 3395–402.10.1182/blood-2007-07-100669]Search in Google Scholar
[28. SANZ M.A. and MONTESINOS P., Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res, 2010. 125: p. S51–S54.10.1016/S0049-3848(10)70013-X]Search in Google Scholar
[29. LEHMANN S., RAVN A., CARLSSON L., ANTUNOVIC P., DENEBERG S., MOLLGARD L., et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011. 25(7): p. 1128–34.10.1038/leu.2011.7821502956]Search in Google Scholar
[30. PARK J.H., QIAO B., PANAGEAS K.S., SCHYMURA M.J., JURCIC J.G., ROSENBLAT T.L., et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011. 118(5): p. 1248–54.10.1182/blood-2011-04-346437379094621653939]Search in Google Scholar
[31. BURNETT A.K., HILLS R.K., GRIMWADE D., JOVANOVIC J.V., CRAIG J., MCMULLIN M.F., et al., Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia, 2013. 27(4): p. 843–851.10.1038/leu.2012.36023222369]Search in Google Scholar
[32. LENGFELDER E., GORLICH D., NOWAK D., SPIEKERMANN K., HAFERLACH C., KRUG U., et al., Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. Eur J Haematol, 2018. 100(2): p. 154–162.10.1111/ejh.1299429114972]Search in Google Scholar
[33. TALLMAN M.S., ANDERSEN J.W., SCHIFFER C.A., APPELBAUM F.R., FEUSNER J.H., WOODS W.G., et al., All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 2002. 100(13): p. 4298–302.10.1182/blood-2002-02-063212393590]Search in Google Scholar
[34. NØRGAARD J.M., FRIIS L.S., KRISTENSEN J.S., SEVERINSEN M.T., MØLLE I., MARCHER C.W., et al., Addressing the room for improvement in management of acute promyelocytic leukemia. European Journal of Haematology, 2019. 102(6): p. 479–485.10.1111/ejh.1322930887583]Search in Google Scholar
[35. REGO E.M., KIM H.T., RUIZ-ARGUELLES G.J., UNDURRAGA M.S., URIARTE MDEL R., JACOMO R.H., et al., Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013. 121(11): p. 1935–43.10.1182/blood-2012-08-44991823319575]Search in Google Scholar